NATCO PHARMA LTD. - 524816 - Update On Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update on Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation under Regulation 30 for appointment/reappointment/cessation of Director(s) NATCO PHARMA LTD. - 524816 - Corporate Action-Board approves Dividend
Record date for the purpose of payment of Third Interim Dividend for the Financial Year 2023-24 NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
outcome of Board Meeting NATCO PHARMA LTD. - 524816 - Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2023
Unaudited Financial Results for the quarter and nine months ended 31st December, 2023 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on Thursday, 15th February 2024 to disseminate Financial Results of the Company for the quarter and nine months ended on 31st December 2023 NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Consider The Unaudited Results For The Quarter And Nine Months Ended 31St December, 2023 And Interim Dividend For The Financial Year 2023-24, If Any
NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 ,inter alia, to consider and approve Consider the Unaudited Results for the quarter and nine months ended 31st December, 2023 and Interim Dividend for the Financial year 2023-24, if any Natco Pharma invests$2 million in Cellogen Therapeutics
Cellogenis primarily involved in two R&D programmes involving cell and gene therapy solutions NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Natco Pharma Limited invests around US$ 2 Million in CELLOGEN THERAPEUTICS PRIVATE LIMITED